RecruitingPhase 2NCT06311981

Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients

A Prospective Phase II Clinical Study of Carbon Ion Radiotherapy for Locally Advanced Non-small Cell Lung Cancer in the Older Adult

Sponsor

Jian Chen

Enrollment

29 participants

Start Date

Aug 8, 2024

Study Type

INTERVENTIONAL

Conditions

Radiotherapy Side Effect Non-small Cell Lung Cancer Older People Carbon Ion Radiotherapy

Summary

To observe the effect and toxicity of carbon ion radiotherapy on local advanced non-small cell lung cancer over 75 years old patients. Systemic therapy could be targeted therapy, chemotherapy or immunotherapy.

Eligibility

Min Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study uses carbon ion radiotherapy — an advanced type of radiation that delivers a more precise and powerful dose to the tumor with less damage to surrounding tissue — for elderly patients (over 75) with locally advanced non-small cell lung cancer who cannot or will not have surgery. **You may be eligible if...** - You are older than 75 years - You have been diagnosed with non-small cell lung cancer (NSCLC) at stage IIb through IIIc (locally advanced but not yet spread to distant organs) - Your cancer has been confirmed by tissue biopsy or cell analysis - You are medically unable to have surgery, or you have declined surgery - Your heart, lung, liver, and kidney function meet the required minimums **You may NOT be eligible if...** - Your cancer has spread to distant organs (metastatic) - You have previously had chest radiation - You have serious autoimmune disease or are on immune-suppressing medications - You have poor lung function below the required thresholds Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONcarbon ion radiotherapy

The patient will receive carbon ion radiotherapy with 70Gy per 20 fractions. Patients with genetic mutations (including but not limited to EGFR, ALK, etc.) should receive targeted therapy as their systemic therapy. For patients who are not suitable for targeted therapy, we recommend single regimen chemotherapy in sequence with radiotherapy. The drugs include etoposide, platinum (carboplatin, cisplatin, nedaplatin or loplatin), vinorelbine, paclitaxel (including liposome paclitaxel and albumin paclitaxel), docetaxel, pemetrexel, gemcitabine, etc. If there is no contraindication to PD-1/PD-L1 immunotherapy, it can be combined with immunotherapy, such as Pembrolizumab. For patients who cannot tolerate chemotherapy, PD-1/PD-L1 immunotherapy is recommended. The progression-free survival rate, toxicity, local control rate, cause-specific survival rate and overall survival rate were observed with regular follow-up after treatment.

OTHERtargeted therapy

targeted therapy

OTHERsingle regimen chemotherapy in sequence with radiotherapy

single regimen chemotherapy in sequence with radiotherapy

Locations(1)

Shanghai Proton and Heavy Ion Center

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06311981

Related Trials

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

NCT0621891418 locations

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

NCT06692738301 locations

OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain

NCT0606804925 locations

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

NCT06561386299 locations

Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers

NCT028388361 location